Non-Alcoholic Steatohepatitis Pipeline Review Market Size, Share, Growth & Trend to 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholic-steatohepatitis-pipeline-review-h2-2015 investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings,
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholic-steatohepatitis-pipeline-review-h2-2015
investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Dynavax Technologies Corporation 40<br />
Enanta Pharmaceuticals, <strong>Inc</strong>. 41<br />
Exicure, <strong>Inc</strong>. 42<br />
Galectin Therapeutics, <strong>Inc</strong>. 43<br />
Galmed International Ltd. 44<br />
Genfit SA 45<br />
GenKyoTex S.A. 46<br />
Gilead Sciences, <strong>Inc</strong>. 47<br />
iCo Therapeutics <strong>Inc</strong>. 48<br />
Immuron Limited 49<br />
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-alcoholicstea<strong>to</strong>hepatitis-pipeline-review-h2-<strong>2015</strong><br />
Intercept Pharmaceuticals, <strong>Inc</strong>. 50<br />
Isis Pharmaceuticals, <strong>Inc</strong>. 51<br />
Jenrin Discovery, <strong>Inc</strong>. 52<br />
Kissei Pharmaceutical Co., Ltd. 53<br />
Kyorin Pharmaceutical Co., Ltd. 54<br />
Merck & Co., <strong>Inc</strong>. 55<br />
Mochida Pharmaceutical Co., Ltd. 56<br />
NGM Biopharmaceuticals, <strong>Inc</strong>. 57<br />
Nimbus Therapeutics, LLC 58<br />
Nippon Chemiphar Co., Ltd. 59<br />
Novartis AG 60<br />
Novo Nordisk A/S 61<br />
ProMetic Life Sciences <strong>Inc</strong>. 62<br />
Protalix BioTherapeutics, <strong>Inc</strong>. 63<br />
Regulus Therapeutics <strong>Inc</strong>. 64<br />
RuiYi <strong>Inc</strong>. 65
Change language